Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted: Clinical Experience from a Spanish Cohort of Expanded Use

Other authors

Institut Català de la Salut

[Vendrell-Serres J, Soto-Angona Ó] Servei de Psiquiatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Psiquiatria, Salut Mental i Addiccions, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Psiquiatria i Medicina Forense, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Rodríguez-Urrutia A, Ramos-Quiroga JA] Servei de Psiquiatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Psiquiatria, Salut Mental i Addiccions, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Psiquiatria i Medicina Forense, Universitat Autònoma de Barcelona, Bellaterra, Spain. Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain. [Inzoli B, López González A] Servei de Psiquiatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-11-11T11:00:37Z

2024-11-11T11:00:37Z

2024



Abstract

Depressive disorder; Esketamine; Treatment-resistant


Trastorno depresivo; Esketamina; Resistente al tratamiento


Trastorn depressiu; Esketamina; Resistent al tractament


Objective: Treatment Resistant Depression (TRD) is commonly defined as the lack of response to two or more anti-depressants with different mechanisms of action. Up to 30% of patients diagnosed with major depressive disorder might be considered to present TRD. The objective of this study was to assess the effectiveness and tolerability of esketamine in patients diagnosed with TRD, who were referred to our program after exhausting all available treatments. A secondary objective consisted in researching the relationship between response and previous use of electroconvulsive therapy. Methods: A prospective, observational study was carried out in patients enrolled in the expanded use of esketamine in our center. They received esketamine prior to its marketing authorisation, for therapeutic purposes. Sixteen subjects were analyzed. Effectiveness was assessed with the Montgomery-Asberg depression rating scale (MADRS). Patients were followed up to 4 months after the administration. Results: Esketamine showed a rapid, robust effect in improving depressive symptoms, with no specific correlation between outcome and any demographic or clinical traits evaluated. No differences were found between patients that previously received Electroconvulsive Therapy, and those that didn’t. 10 out of 16 patients responded (> 50% change in baseline MADRS scores), but only five achieved remission (< 12 points in the global MADRS score). We provide some recommendations, based on clinical experience, to improve tolerability and adherence, and to manage adverse effects. Conclusion: Results suggest that esketamine is a safe, effective and rapid-acting option for TRD. More studies are needed to properly assess predictors of response outcome.

Document Type

Article


Published version

Language

English

Publisher

Korean College of Neuropsychopharmacology

Related items

Clinical Psychopharmacology and Neuroscience;22(1)

https://doi.org/10.9758/cpn.23.1097

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial 4.0 International

http://creativecommons.org/licenses/by-nc/4.0/

This item appears in the following Collection(s)